Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Will Chart Analysts Notice Bad Omen on Sanofi's Chart
11:52am, Friday, 08'th Oct 2021
If history is any guide, there may be trouble ahead for shares of Sanofi(NASDAQ:SNY). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.
Giving Moderna's COVID-19 booster at the same time as Sanofi's flu is safe and effective
10:38am, Friday, 08'th Oct 2021
U.S.-listed shares of Sanofi SNY, +0.37% gained 0.4% in trading on Friday after it announced that co-administering a flu shot with Moderna Inc.'s MRNA, -3.33% experimental COVID-19 booster in seniors
EXG: American Market Continues To Be Overvalued, Go Abroad With This Fund
06:13am, Wednesday, 06'th Oct 2021
EXG: American Market Continues To Be Overvalued, Go Abroad With This Fund
After COVID-19, Could This Be the Next Billion-Dollar Vaccine Market?
06:00am, Monday, 04'th Oct 2021
Three healthcare giants are vying for the prize.
Here's a High-Yield Dividend Stock Wall Street Thinks Could Jump 26% Within 12 Months
05:52am, Monday, 04'th Oct 2021
There's plenty to like with this big pharma stock -- but a few problem spots, too.
3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health
11:08am, Thursday, 30'th Sep 2021
Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.
Are Investors Undervaluing Sanofi (SNY) Right Now?
01:33pm, Wednesday, 29'th Sep 2021
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Sanofi Stops Work On Its mRNA COVID-19 Vaccine: What You Need To Know
07:53am, Tuesday, 28'th Sep 2021
Sanofi SA (NASDAQ: SNY) is dropping plans for its mRNA-based COVID-19 vaccine because it believes it will be too late in reaching the market, STAT news reported. Sanofi says that the market is well-
Sanofi halts development of its Covid mRNA vaccine
07:39am, Tuesday, 28'th Sep 2021
CNBC's Charlotte Reed reports on Sanofi's announcement that its Covid-19 mRNA vaccine will not pursue phase 3 trials despite positive initial results. Instead the French pharma firm said it wants to f
Sanofi ditches mRNA COVID-19 vaccine amid rivals' success
05:10am, Tuesday, 28'th Sep 2021
Sanofi is dropping plans for its own mRNA-based COVID-19 vaccine because of the dominant role of the BioNTech-Pfizer alliance as well as Moderna in the fight against the pandemic, the company said on
Sanofi reports encouraging early results for COVID-19 mRNA vaccine candidate
02:34am, Tuesday, 28'th Sep 2021
Sanofi said Tuesday that it recorded positive interim results from an early study into its first mRNA-based Covid-19 vaccine candidate.
Analyst Upgrades Sanofi On COVID-19 Vaccine Optimism
12:01pm, Monday, 27'th Sep 2021
Sanofi SA (NASDAQ:SNY) shares traded higher by 0.4% on Monday after the company scored an analyst upgrade. The Analyst: SVB Leerink analyst Geoffrey Porges upgraded Sanofi from Market Perform to Outpe
5 European Dividend Aristocrats Offer Huge Income and Growth Potential
07:27am, Monday, 27'th Sep 2021
With September and the third quarter almost over, many investors are looking to the fourth quarter and beyond.
Sanofi: Availability of the Q3 2021 Memorandum for modelling purposes
01:30am, Friday, 24'th Sep 2021
Availability of the Q 3 202 1 Memorandum for modelling purposes
Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC
06:45am, Monday, 20'th Sep 2021
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) hope to expand Libtayo into a broader population with a chemo combo regimen. According to data released at the European So
